Characterization of breast cancer DNA content profiles as a prognostic tool

Experimental Oncology

Volumn 36, Issue 4, 2014, Pages 219-255

  Gerashchenko, B I ^a,b   Huna, A ^a   Erenpreisa, J ^a  

^a LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

^b R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Aneuploidy; Breast cancer; DNA content analysis; DNA histogram; Flow cytometry; Image cytometry

Indexed keywords

ANEUPLOIDY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER STEM CELL; CANCER TISSUE; CHROMOSOMAL INSTABILITY; DNA CONTENT; DNA DETERMINATION; ENDOREDUPLICATION; EVALUATION STUDY; FLOW CYTOMETRY; HISTOGRAM; HUMAN; IMAGE CYTOMETRY; BREAST NEOPLASMS; FEMALE; GENETICS; PLOIDY; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; PLOIDIES; PROGNOSIS;

EID: 84920128407     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
2. Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet 2012; 13: 189-203.
3. Salmina K, Jankevics E, Huna A, et al. Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumor cells. Exp Cell Res 2010; 316: 2099-112.
4. Erenpreisa J, Salmina K, Huna A, et al. Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation. Cell Biol Int 2011; 35: 687-95.
5. Lagadec C, Vlashi E, Della Donna L, et al. Radiationinduced reprogramming of breast cancer cells. Stem Cells 2012; 30: 833-44.
6. Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507.
7. Coward J, Harding A. Size does matter: why polyploid tumor cells are critical drug targets in the war on cancer. Front Oncol 2014; 4: Article 123. doi: 10.3389/fonc.2014.00123.
8. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-7.
9. Yoon D-S, Wersto RP, Zhou W, et al. Variable levels of chromosomal instability and mitotic spindle checkpoint defects in breast cancer. Am J Pathol 2002; 161: 391-7.
10. Thompson SL, Bakhoum SF, Compton DA. Mechanisms of chromosomal instability. Curr Biol 2010; 20: R285-R295.
11. Hansemann D. Ueber asymmetrische Zelltheilung in Epithelkrebsen und deren biologische Bedeutung. Virschows Arch Pathol Anat 1890; 119: 299-326.
12. Boveri T. Uber mehrpolige Mitosen als Mittel zur Analyse des Zellkerns. Verh Physi-med Ges Würzburg NF 1902; 35: 67-90.
13. Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev 2007; 17: 157-62.
14. Ganem NJ, Pellman D. Linking abnormal mitosis to the acuisition of DNA damage. J Cell Biol 2012; 199: 871-81.
15. Siegel JJ, Amon A. New insights into the troubles of aneuploidy. Annu Rev Cell Dev Biol 2012; 28: 189-214.
16. Weaver BAA, Cleveland DW. Does aneuploidy cause cancer? Curr Opin Cell Biol 2006; 18: 658-67.
17. Ricke RM, van Ree JH, van Deursen JM. Whole chromosome instability and cancer: a complex relationship. Trends Genet 2008; 24: 457-66.
18. Storchova Z, Kuffer C. The consequences of tetraploidy and aneuploidy. J Cell Sci 2008; 121 (Pt23): 3859-66.
19. Tang YC, Williams BR, Siegel JJ, et al. Identification of aneuploidy-selective antiproliferation compounds. Cell 2011; 144: 499-512.
20. Haroske G, Baak JPA, Danielsen H, et al. Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Anal Cell Pathol 2001; 23: 89-95.
21. Li Y, Benezra R. Identification of a human mitotic checkpoint gene: hsMAD2. Science 1996; 274: 246-8.
22. Wang R-H, Yu H, Deng C-X. A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc Natl Acad Sci USA 2004; 101: 17108-13.
23. Daniels MJ, Wang Y, Lee M, et al. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 2004; 306: 876-9.
24. Ichikawa D, Hashimoto N, Hoshima M, et al. Analysis of numerical aberrations in specific chromosomes by fluorescent in situ hybridization as a diagnostic tool in breast cancer. Cancer 1996; 77: 2064-9.
25. Persons DL, Robinson RA, Hsu PH, et al. Chromo-some-specific aneusomy in carcinoma of the breast. Clin Cancer Res 1996; 2: 883-8.
26. Nakopoulou L, Tsirmpa I, Giannopoulou I, et al. Aneuploidy of chromosome 20 in invasive breast cancer correlates with poor outcome. Cancer Genet Cytogenet 2002; 134: 127-32.
27. Reinholz MM, Bruzek AK, Visscher DW, et al. Breast cancer and aneusomy 17: Implications for carcinogenesis and therapeutic response. Lancet Oncol 2009; 10: 267-77.
28. Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 ane usomy is associated with poor prognostic factors in inva sive breast carcinoma. Breast Cancer Res Treat 2003; 77: 109-14.
29. Thompson DA, Desai MM, Murray AW. Ploidy controls the success of mutators and nature of mutations during budding yeast evolution. Curr Biol 2006; 16: 1581-90.
30. Davoli T, de Lange T. The causes and consequences of polyploidy in normal development and cancer. Annu Rev Cell Dev Biol 2011; 27: 585-610.
31. Erenpreisa J, Cragg MS. Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal. Cancer Cell Int 2013; 13: Article 92. doi: 10.1186/1475-2867-13-92.
32. Huna A, Salmina K, Jascenko E, et al. Self-renewal signalling in presenescent tetraploid IMR90 cells. J Aging Res 2011; 2011: Article ID 103253. doi: 10.4061/2011/103253.
33. Jonsdottir AB, Stefansson OA, Bjornsson J, et al. Tetraploidy in BRCA2 breast tumors. Eur J Cancer 2012; 48: 305-10.
34. Auer GU, Caspersson TO, Wallgren AS. DNA content and survival in mammary carcinoma. Anal Quant Cytol 1980; 2: 161-5.
35. Boon ME, Auer GU, van Kaam H, et al. Classifying breast carcinomas with DNA measurements and morphometry. Cytometry 1984; 5: 469-72.
36. Opfermann M, Brugal G, Vassilakos P. Cytometry of breast carcinoma: Significance of ploidy balance and proliferation index. Cytometry 1987; 8: 217-24.
37. Auer GU, Fallenius AG, Erhardt KY, et al. Progression of mammary adenocarcinomas as reflected by nuclear DNA content. Cytometry 1984; 5: 420-5.
38. Barlogie B, Hittelman W, Spitzer G, et al. Correlation of DNA distribution abnormalities with cytogenetic findings in human adult leukemia and lymphoma. Cancer Res 1977; 37: 4400-7.
39. Barlogie B, Göhde W, Johnston DA, et al. Determination of ploidy and proliferative characteristics of human solid tumors by pulse cytophotometry. Cancer Res 1978; 38: 3333-9.
40. Fernö M, Baldetorp B, Borg A, et al. Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and clinical outcome. Acta Oncol 1992; 31: 157-65.
41. Baisch H, Göhde W, Linden WA. Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys 1975; 12: 31-9.
42. McDivitt RW, Stone KR, Meyer JS. A method for dissociation of viable breast cancer cells that produces flow cytometric information similar to that obtained by thymidine labeling. Cancer Res 1984; 44: 2628-33.
43. McDivitt RW, Stone KR, Craig RB, et al. A comparison of human breast cancer cell kinetics measured by flow cytometry and thymidine labeling. Lab Invest 1985; 52: 287-91.
44. Gentili C, Sanfilippo O, Silvestrini R. Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer 1981; 48: 974-9.
45. Tubiana M, Pejovic MH, Chavaudra N, et al. The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer 1984; 33: 441-5.
46. Hedley DW, Rugg CA, Gelber RD. Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res 1987; 47: 4729-35.
47. Merkel DE, Dressler LG, McGuire WL. Flow cytometry, cellular DNA content, and prognosis in human malignancy. J Clin Oncol 1987; 5: 1690-703.
48. Clark GM, Dressler LG, Owens MA, et al. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989; 320: 627-33.
49. Sigurdsson H, Baldetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322: 1045-53.
50. Sigurdsson H, Baldetorp B, Borg A, et al. Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels. Br J Cancer 1990; 62: 786-90.
51. O'Reilly SM, Camplejohn RS, Barnes DM, et al. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer 1990; 61: 671-4.
52. Wenger CR, Clark GM. S-phase fraction and breast cancer - a decade of experience. Breast Cancer Res Treat 1998; 51: 255-65.
53. Fallenius AG, Auer GU, Carstensen JM. Prognostic significance of DNA measurements in 409 consecutive breast cancer patients. Cancer 1988; 62: 331-41.
54. Joensuu H, Toikkanen S, Klemi PJ. DNA index and S-phase fraction and their combination as prognostic factors in operable ductal breast carcinoma. Cancer 1990; 66: 331-40.
55. Coulson PB, Thornthwaite JT, Woolley TW, et al. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival. Cancer Res 1984; 44: 4187-96.
56. Stal O, Wingren S, Carstensen J, et al. Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer. Eur J Cancer Clin Oncol 1989; 25: 301-9.
57. Kallioniemi O-P, Blanco G, Alavaikko M, et al. Tumor DNA ploidy as an independent prognostic factor in breast cancer. Br J Cancer 1987; 56: 637-42.
58. Baildam AD, Zaloudik J, Howell A, et al. DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. Br J Cancer 1987; 55: 553-9.
59. Ewers S-B, Langström E, Baldetorp B, et al. Flowcytometric DNA analysis in primary breast carcinomas and clinicopathological correlations. Cytometry 1984; 5: 408-19.
60. Ross JS, Linette GP, Stec J, et al. DNA ploidy and cell cycle analysis in breast cancer. Am J Clin Pathol 2003; 120 (Suppl 1): S72-S84.
61. Stanton PD, Cooke TG, Oakes SJ, et al. Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer. Br J Cancer 1992; 66: 925-9.
62. Kallioniemi O-P. Comparison of fresh and paraffinembedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. Cytometry 1988; 9: 164-9.
63. Feulgen R, Rossenbeck H. Mikroskopisch-chemischer Nachweis einer Nukleinsäure von Typus der Thymonukleinsäure und die darauf beruhende selektive Färbung von Zellkernen in mikroskopischen Präparaten. Hoppe-Seylers Z Physiol Chem 1924; 135: 203-48.
64. Haugland RP. Handbook of Fluorescent Probes and Research Products, 9th ed. Eugene, OR: Molecular Probes; 2002: 265-352.
65. Dressler LG, Seamer L, Owens MA, et al. Evaluation of modeling system for S-phase estimation in breast cancer by flow cytometry. Cancer Res 1987; 47: 5294-302.
66. Ormerod MG (editor). Flow cytometry: a practical approach, 3rd ed. Oxford: University Press; 2000, 296 p.
67. MacGrogan G, Jollet I, Huet S, et al. Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma. Mod Pathol 1997; 10: 769-76.
68. Dawson AE, Norton JA, Weinberg DS. Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry. Am J Pathol 1990; 136: 1115-24.
69. Chen T-L, Luo I, Mikhail N, et al. Comparison of flow and image cytometry for DNA content analysis of fresh and formalin-fixed, paraffin-embedded tissue in breast carcinoma. Cytometry 1995; 22: 181-9.
70. Cope C, Rowe D, Delbridge L, et al. Comparison of image analysis and flow cytometric determination of cellular DNA content. J Clin Pathol 1991; 44: 147-51.
71. Yogesan K, Jorgensen T, Albregtsen F, et al. Entropybased texture analysis of chromatin structure in advanced prostate cancer. Cytometry 1996; 24: 268-76.
72. Pienta KJ, Partin AW, Coffey DS. Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res 1989; 49: 2525-32.
73. Nielsen B, Albregtsen F, Danielsen HE. Statistical nuclear texture analysis in cancer research: A review of methods and applications. Crit Rev Oncog 2008; 14: 89-164.
74. Nielsen B, Albregtsen F, Kildal W, et al. The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer. Anal Cell Path 2012; 35: 305-14.